Insulin-Like Growth Factor System in Cancer: Novel Targeted Therapies

@article{Brahmkhatri2015InsulinLikeGF,
  title={Insulin-Like Growth Factor System in Cancer: Novel Targeted Therapies},
  author={Varsha P. Brahmkhatri and Chinmayi Prasanna and Hanudatta S. Atreya},
  journal={BioMed Research International},
  year={2015},
  volume={2015}
}
Insulin-like growth factors (IGFs) are essential for growth and survival that suppress apoptosis and promote cell cycle progression, angiogenesis, and metastatic activities in various cancers. The IGFs actions are mediated through the IGF-1 receptor that is involved in cell transformation induced by tumour. These effects depend on the bioavailability of IGFs, which is regulated by IGF binding proteins (IGFBPs). We describe here the role of the IGF system in cancer, proposing new strategies… 
Disrupting Insulin and IGF Receptor Function in Cancer
TLDR
The well-studied role of the IGF system in regulating malignancies, the limitations on the current strategies of blocking the insulin-like growth factor system in cancer, and the potential future directions for targeting the IGF System are reviewed.
Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies
TLDR
The preclinical and clinical experience with IGF-targeted therapies to-date are reviewed, and the rationale for future combination approaches as a means to overcome treatment resistance is discussed.
Growth hormone, insulin-like growth factor system and carcinogenesis.
TLDR
While ample experimental evidence supports a role of the GH-IGF system in tumour promotion and progression, the strength of evidence from patients with acromegaly, GH deficiency, or treated with GH is much weaker.
The insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies
Breast cancer is the most common cancer and the second leading cause of cancer-related deaths among women worldwide. Although patients are often diagnosed in the early and curable stages, the
The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential
TLDR
Increasing preclinical evidence indicates that IGF-I is also involved in the development of drug resistance against current standard-of-care agents against MM, including proteasome inhibitors, immunomodulatory agents, and corticoids.
Role of the IGF-1 Axis in Overcoming Resistance in Breast Cancer
TLDR
An overview of the most recent and significant field of application of IGF-1 inhibitors and relevant therapeutic strategies is offered, weighing their possible future impact on clinical practice.
Insulin/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer
TLDR
This review highlights the stroma-derived IGF signaling and IGF-binding proteins as potential novel therapeutic targets in PDAC.
Revisiting the IGF-1R as a breast cancer target
TLDR
Monoclonal antibodies and tyrosine kinase inhibitors targeting insulin-like growth factor-1 receptor failed in phase III breast clinical trials, and these drugs are not being further developed likely due to their metabolic toxicities.
Insulin‐like growth factor axis targeting in cancer and tumour angiogenesis – the missing link
TLDR
The contribution of this signalling axis to tumour angiogenesis, the mechanisms of resistance to therapy and the interplay with other pro‐angiogenic pathways are reviewed to offer insight in the renewed interest in the application of IGF axis targeting agents in anti‐cancer combination therapies.
...
...

References

SHOWING 1-10 OF 275 REFERENCES
Defining the pathway to insulin-like growth factor system targeting in cancer.
Targeting the insulin growth factor receptor 1.
Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment
TLDR
Approaches to target the type 1 insulin-like growth factor receptor using antibodies, small molecule inhibitors of the IGF1R tyrosine kinase, and molecular agents such as antisense and small interfering RNAs are described.
Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer
TLDR
Key issues include identification of factors that influence sensitivity to IGF 1R blockade, and how most effectively to combine IGF1R inhibitors with other treatments.
Targeting the insulin-like growth factor-1 receptor in human cancer
  • A. Arcaro
  • Biology, Medicine
    Front. Pharmacol.
  • 2013
TLDR
The role of the IGF signaling system in human cancer and the main strategies which have been so far evaluated to target the IGF-1R are discussed.
Role of the insulin-like growth factor family in cancer development and progression.
  • H. YuT. Rohan
  • Biology, Medicine
    Journal of the National Cancer Institute
  • 2000
TLDR
Evidence suggests that certain lifestyles, such as one involving a high-energy diet, may increase IGF-I levels, a finding that is supported by animal experiments indicating that IGFs may abolish the inhibitory effect of energy restriction on cancer growth.
Insulin-like growth factor-binding protein-6 and cancer.
TLDR
Understanding of the mechanisms underlying the actions of the IGF ligands, receptors and binding proteins, including IGFBP-6, will enhance the ability to develop optimal treatments that can be targeted to the most appropriate patients.
Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy: advances and perspectives.
TLDR
The application of network pharmacology methods is proposed to reconsider the clinical use of inhibitors with concomitant IR inhibition or other kinases inhibition, hoping that more optimal combinations would be obtained for cancer therapy.
Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor
TLDR
This review will focus on the next promising therapeutic target, the insulin-like growth factor I receptor (IGF-IR), which has been implicated in a number of neoplastic diseases, including several common carcinomas.
Insulin-like growth factors and neoplasia
TLDR
Converging results from epidemiological research and in vivo carcinogenesis models indicate that high levels of circulating IGF1 are associated with increased risk of several common cancers, and ongoing research seeks to clarify the mechanisms underlying these observations.
...
...